Original ArticlePrognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab
Under an Elsevier user license
open archive
Key Words
Prognostic models
Nomograms
Non–small-cell lung cancer
Chemotherapy
Bevacizumab
Cited by (0)
Disclosure: The authors declare no conflict of interest.
This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Copyright © 2012 International Association for the Study of Lung Cancer. All rights reserved.